Stay updated with breaking news from Open Label. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS
A recent study captured the dynamics of pre-symptomatic SARS-CoV-2 emissions and reported the extent, magnitude, and routes of viral transmission are heterogeneous, with nasal mucosa being an important source of viral transmission.
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studies HMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 7, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative...
WALTHAM, Mass., Aug. 22, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the
WALTHAM, Mass., Aug. 22, 2022 -- Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today... | August 22, 2022